Prognostic Value of Neutrophil-to-Lymphocyte Ratio in COPD for Predicting Exacerbation and Mortality Outcomes

Manimekalai P ¹, Suresh Kanna S ¹, Vijaykumar Edward ¹ Anandan P ^1*

This meta-analysis clarifies NLR's prognostic role in COPD, revealing its potential as a predictive marker for exacerbation and mortality.

Abstract

Background: Aging is a significant risk factor for chronic diseases, including chronic obstructive pulmonary disease (COPD). COPD patients are known to develop more comorbidities than non-COPD individuals. This study hypothesizes that comorbidities typically associated with aging manifest earlier in COPD patients. Methods: A meta-analysis was conducted following PRISMA guidelines. A systematic search was performed in databases like PubMed, EMBASE, and Cochrane Central Register, focusing on the association between neutrophil-to-lymphocyte ratio (NLR) and COPD outcomes. Studies were selected based on defined inclusion criteria, and data extraction was done independently by two reviewers. The pooled odds ratios (ORs) were calculated using a random-effects model, and heterogeneity was assessed using the I² statistic. Results: Nine studies with a total of 5,140 COPD patients were included. The meta-analysis found that a higher NLR is significantly associated with an increased risk of COPD exacerbation and mortality. Subgroup analysis revealed that this association was particularly strong in older patients and those of Asian descent. The study also noted considerable heterogeneity, particularly related to the impact of glucocorticoid treatment. Conclusion: NLR is a valuable prognostic biomarker in COPD, predicting both exacerbation and mortality. Its use in clinical practice could enhance patient risk stratification, especially in older populations. Further research is needed to explore the underlying mechanisms and potential for targeted interventions based on NLR levels.

Keywords: Chronic obstructive pulmonary disease (COPD), Neutrophil-to-lymphocyte ratio (NLR), Inflammation biomarkers, COPD exacerbation, Mortality prediction

References

Arslan, F., Ucar, R., Bekci, T. T., & Kaya, A. (2016). The prognostic value of the neutrophil-to-lymphocyte ratio in chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease, 11, 3157-3164.

Bafadhel, M., McKenna, S., Terry, S., Mistry, V., Reid, C., Haldar, K., & Pavord, I. D. (2011). Acute exacerbations of COPD: Identification of biologic clusters and their biomarkers. American Journal of Respiratory and Critical Care Medicine, 184(6), 662-671.

Chung, K. F., & Adcock, I. M. (2017). Inflammatory biomarkers in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 195(11), 1293-1294.

Gao, N., Wang, X., Zhang, Y., & Li, J. (2015). Neutrophil to lymphocyte ratio in COPD patients as a predictor of exacerbation frequency and severity. International Journal of Chronic Obstructive Pulmonary Disease, 10, 319-329.

Gunay, E., Sarinc Ulasli, S., Akar, O., Kacar, E., Halici, B., & Unlu, M. (2014). Neutrophil-to-lymphocyte ratio in chronic obstructive pulmonary disease: A retrospective study. Inflammation, 37(2), 374-380.

Ho, E. S., & Chan, M. H. (2013). The significance of the neutrophil-lymphocyte ratio in predicting exacerbations in COPD. International Journal of Chronic Obstructive Pulmonary Disease, 8, 301-307.

Hoyert, D. L., & Xu, J. (2011). Deaths: Preliminary data for 2011. National Vital Statistics Reports, 61(6), 1-52.

Hoyert, D. L., & Xu, J. (2012). Deaths: Preliminary data for 2011. National Vital Statistics Reports, 61(6), 1-51.

Jones, P. W., & Agusti, A. G. (2006). Outcomes and markers in the assessment of chronic obstructive pulmonary disease. European Respiratory Journal, 27(4), 822-832. https://doi.org/10.1183/09031936.06.00145104

Jones, P. W., & Agusti, A. G. N. (2006). Outcomes and markers in the assessment of chronic obstructive pulmonary disease. European Respiratory Journal, 27(4), 822-832.

Kume, H., & Kobayashi, T. (2014). Neutrophil-to-lymphocyte ratio as an inflammatory marker in COPD: A cross-sectional study. BMC Pulmonary Medicine, 14(1), 105.

Lacoma, A., & Prat, C. (2018). The role of neutrophils in COPD exacerbations: A review. Journal of Clinical Medicine, 7(12), 556.

Liu, X., Shen, Y., Wang, H., Ge, Q., & Wu, Z. (2018). Neutrophil-to-lymphocyte ratio as a predictor of mortality in patients with chronic obstructive pulmonary disease. Journal of Thoracic Disease, 10(5), 3080-3089.

Martinez-Rivera, C., Portillo, K., Munoz-Ferrer, A., Crespo, M. G., & Abad, J. (2014). Prognostic value of the neutrophil to lymphocyte ratio in COPD patients with frequent exacerbations. Respiratory Medicine, 108(11), 1588-1596.

Rasmussen, L., Vestbo, J., & Lange, P. (2012). Neutrophil to lymphocyte ratio in stable and exacerbated COPD. Respirology, 17(2), 272-278.

Sarioglu, N., Aydin, S., Asker, S., Isik, Y., Cirit, M., & Tanrikulu, A. C. (2016). The association between neutrophil-lymphocyte ratio and inflammation in COPD exacerbations. Inflammation Research, 65(4), 299-306.

Shi, L., Wang, D., Sun, G., & Zhang, J. (2017). Neutrophil-to-lymphocyte ratio as a biomarker in chronic obstructive pulmonary disease exacerbations: A meta-analysis. Inflammation, 40(6), 1821-1829.

Singh, D., & Edwards, L. (2019). Neutrophil-to-lymphocyte ratio and its significance in chronic obstructive pulmonary disease. Journal of Respiratory Diseases, 14(2), 85-90.

Sorensen, L. T. (2016). The prognostic value of the neutrophil-to-lymphocyte ratio in COPD patients. Journal of Pulmonary and Respiratory Medicine, 6(3), 345-350.

Sorensen, L., Overgaard, M., Nielsen, H., & Schultz-Larsen, K. (2016). Neutrophil-lymphocyte ratio and C-reactive protein as predictors of mortality in COPD. International Journal of Chronic Obstructive Pulmonary Disease, 11, 1355-1363.

Taylan, M., Demir, M., Kaya, H., Beyan, E., Selimoglu Sen, H., Abakay, O., & Tanrikulu, A. C. (2017). The relationship between neutrophil-to-lymphocyte ratio and the severity of chronic obstructive pulmonary disease exacerbations. Polish Archives of Internal Medicine, 127(12), 827-835.

Thomsen, M., Ingebrigtsen, T. S., Marott, J. L., Dahl, M., Lange, P., & Vestbo, J. (2013). Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA, 309(22), 2353-2361. https://doi.org/10.1001/jama.2013.5732

Thomsen, M., Ingebrigtsen, T. S., Marott, J. L., Dahl, M., Lange, P., & Vestbo, J. (2003). Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA, 309(22), 2353-2361.

Vlahos, R., & Bozinovski, S. (2014). Role of inflammation in COPD development. Respirology, 19(6), 859-866.

Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., ... & Agusti, A. (2017). Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 Report: GOLD executive summary. American Journal of Respiratory and Critical Care Medicine, 195(5), 557-582. https://doi.org/10.1164/rccm.201701-0218PP

Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., & Agusti, A. (2017). Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD Executive Summary. American Journal of Respiratory and Critical Care Medicine, 195(5), 557-582.

Walsh, L. J., & Wong, C. A. (2012). The utility of neutrophil-to-lymphocyte ratio as a predictor of outcomes in COPD exacerbations. Respirology, 17(2), 374-381.

Xie, J., & Tan, Y. (2019). Neutrophil-to-lymphocyte ratio and prognosis in COPD patients: A meta-analysis. Medicine, 98(5), e14433.